Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

NCT02014844 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: 250 mg/m2 aldoxorubicin
DRUG: 350 mg/m2 aldoxorubicin

Sponsor

ImmunityBio, Inc.